Advisors Asset Management, Inc. - NOVOCURE LTD ownership

NOVOCURE LTD's ticker is NVCR and the CUSIP is G6674U108. A total of 3 filers reported holding NOVOCURE LTD in Q4 2023. The put-call ratio across all filers is - and the average weighting 0.0%.

Quarter-by-quarter ownership
Advisors Asset Management, Inc. ownership history of NOVOCURE LTD
ValueSharesWeighting
Q3 2023$18,815
-91.6%
1,165
-68.8%
0.00%
-100.0%
Q1 2023$224,262
-39.9%
3,729
-26.7%
0.01%
-37.5%
Q4 2022$373,352
-63.0%
5,090
-61.7%
0.01%
-61.9%
Q3 2022$1,010,000
+7.1%
13,293
-2.0%
0.02%
+16.7%
Q2 2022$943,000
-17.9%
13,571
-2.0%
0.02%0.0%
Q1 2022$1,148,000
-42.3%
13,851
-47.8%
0.02%
-35.7%
Q4 2021$1,991,000
-43.0%
26,516
-11.9%
0.03%
-47.2%
Q3 2021$3,496,000
-56.3%
30,092
-16.6%
0.05%
-55.1%
Q2 2021$8,000,000
+57.2%
36,066
-6.3%
0.12%
+49.4%
Q1 2021$5,089,000
-30.3%
38,500
-8.8%
0.08%
-34.7%
Q4 2020$7,303,000
+52.5%
42,202
-1.9%
0.12%
+36.0%
Q3 2020$4,790,000
+48.6%
43,033
-20.9%
0.09%
+41.3%
Q2 2020$3,224,000
-29.6%
54,372
-20.0%
0.06%
-42.2%
Q1 2020$4,577,000
-17.7%
67,975
+3.0%
0.11%
+11.2%
Q4 2019$5,563,000
-5.6%
66,012
-16.2%
0.10%
-9.3%
Q3 2019$5,890,000
+20.8%
78,770
+2.1%
0.11%
+22.7%
Q2 2019$4,877,000
+40.6%
77,136
+7.1%
0.09%
+41.9%
Q1 2019$3,469,000
+76.0%
72,021
+22.4%
0.06%
+55.0%
Q4 2018$1,971,000
-7.1%
58,861
+45.4%
0.04%
+14.3%
Q3 2018$2,121,000
+481.1%
40,478
+247.4%
0.04%
+483.3%
Q2 2018$365,00011,6530.01%
Other shareholders
NOVOCURE LTD shareholders Q4 2023
NameSharesValueWeighting ↓
Invus Financial Advisors, LLC 350,884$77,833,00015.51%
HARTLINE INVESTMENT CORP/ 302,194$67,033,0008.47%
Darsana Capital Partners LP 700,000$155,274,0004.42%
MORGAN JESS S & CO INC 23,775$5,274,0003.47%
Soleus Capital Management, L.P. 98,975$21,955,0003.38%
Montanaro Asset Management Ltd 116,650$25,875,0003.26%
Taylor Frigon Capital Management LLC 31,035$6,884,0002.15%
Rhenman & Partners Asset Management AB 120,000$26,618,0001.81%
COURAGE CAPITAL MANAGEMENT LLC 10,000$2,218,0001.33%
Derbend Asset Management 5,789$1,284,0001.20%
View complete list of NOVOCURE LTD shareholders